JP2021524855A5 - - Google Patents

Info

Publication number
JP2021524855A5
JP2021524855A5 JP2020564888A JP2020564888A JP2021524855A5 JP 2021524855 A5 JP2021524855 A5 JP 2021524855A5 JP 2020564888 A JP2020564888 A JP 2020564888A JP 2020564888 A JP2020564888 A JP 2020564888A JP 2021524855 A5 JP2021524855 A5 JP 2021524855A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dantrolene
administration
pharmaceutically acceptable
composition according
Prior art date
Application number
JP2020564888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524855A (ja
JPWO2019226621A5 (https=
JP7762489B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033260 external-priority patent/WO2019226621A1/en
Publication of JP2021524855A publication Critical patent/JP2021524855A/ja
Publication of JPWO2019226621A5 publication Critical patent/JPWO2019226621A5/ja
Publication of JP2021524855A5 publication Critical patent/JP2021524855A5/ja
Priority to JP2023191895A priority Critical patent/JP2024023270A/ja
Application granted granted Critical
Publication of JP7762489B2 publication Critical patent/JP7762489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564888A 2018-05-21 2019-05-21 ダントロレン製剤およびその使用方法 Active JP7762489B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191895A JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862674394P 2018-05-21 2018-05-21
US62/674,394 2018-05-21
PCT/US2019/033260 WO2019226621A1 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191895A Division JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Publications (4)

Publication Number Publication Date
JP2021524855A JP2021524855A (ja) 2021-09-16
JPWO2019226621A5 JPWO2019226621A5 (https=) 2022-05-25
JP2021524855A5 true JP2021524855A5 (https=) 2022-05-25
JP7762489B2 JP7762489B2 (ja) 2025-10-30

Family

ID=66821419

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564888A Active JP7762489B2 (ja) 2018-05-21 2019-05-21 ダントロレン製剤およびその使用方法
JP2023191895A Pending JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191895A Pending JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Country Status (15)

Country Link
US (1) US20210236467A1 (https=)
EP (1) EP3796889A1 (https=)
JP (2) JP7762489B2 (https=)
KR (1) KR20210011961A (https=)
CN (1) CN112135605A (https=)
AU (1) AU2019272577B2 (https=)
BR (1) BR112020023012A2 (https=)
CA (1) CA3101093A1 (https=)
IL (1) IL278575B1 (https=)
MA (1) MA52707A (https=)
MX (2) MX2020012464A (https=)
SG (1) SG11202011121UA (https=)
UA (1) UA127661C2 (https=)
WO (1) WO2019226621A1 (https=)
ZA (1) ZA202006986B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英（江苏）药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1361092A (en) 1992-03-10 1993-10-05 Kyukyu Pharmaceutical Co., Ltd. Pharmaceutical preparation for percutaneous administration
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Similar Documents

Publication Publication Date Title
US11992480B2 (en) Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
JP7008988B2 (ja) ソフト抗コリン作用性エステルの投与の方法および使用
JP2022105175A5 (https=)
JP7192049B2 (ja) 眼科用組成物
CN106038476B (zh) 安全和有效治疗红斑的改进的方法和组合物
IL274045B2 (en) Prodrugs of dantrolene and methods of using them
JP2018520198A5 (https=)
US20230225962A1 (en) Methods of administering an aripiprazole injectable preparation
JP2011219364A (ja) 経皮吸収促進剤、および該経皮吸収促進剤を含有する経皮製剤
CN105473144A (zh) 用于加速斑块消退的组合物和治疗方法
US12042487B2 (en) Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20140094438A1 (en) Compositions and methods for the treatment of pain
JP2021524855A5 (https=)
CN110169962A (zh) 用于治疗癌症的氧烯洛尔组合物
JP2008528489A (ja) Ｑｔ間隔調節方法
Buskila Drug therapy
JPWO2019226621A5 (https=)
JP2020535139A (ja) シポニモドの投与レジメン
RU2020141883A (ru) Композиции дантролена и способы их применения
EP2338473B9 (en) Pharmaceutical dosage forms of tizanidine and administration route thereof
US20230000796A1 (en) Intranasal administration of ketamine to cluster headache patients
WO2010042841A1 (en) Combination therapies for the treatment of degenerative inflammatory conditions of the nervous system
Knotkova et al. Safety of the transcranial direct current stimulation (tDCS): evaluation of 815 tDCS sessions in 100 chronic-pain patients
KR20250168633A (ko) 근육 세포 내 유트로핀의 수준을 상향 조절하기 위한 화합물 및 이의 적용 방법
JPWO2022005807A5 (https=)